RxDoctor Payments Data

Sanjaya Khanal, MD

Cardiovascular Disease · Lancaster, CANPI 1952460248

Payments from drug & device makers

$137,213in general payments, 2019–2025

Across 171 payments — averaging $802.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$127K
  • Medtronic$4K
  • Abbott$3K
  • Edwards Lifesciences$2K
  • Boston Scientific$687
  • E.r. Squibb & Sons, L.L.C.$253
  • plus $823 from 14 others

What the payments were for

  • Travel & lodging$5,81756%
  • Food & beverage$4,46243%
  • Education$420%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$137,213 in reported general payments places this provider in the 90th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$433,908
Medicare patients
1,049
Services billed
3,272

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin240$328,790
EliquisApixaban189$221,947
OzempicSemaglutide163$191,390
XareltoRivaroxaban117$170,101
SynjardyEmpagliflozin/Metformin Hcl138$165,686
EntrestoSacubitril/Valsartan77$128,856
FarxigaDapagliflozin Propanediol37$51,790
MounjaroTirzepatide25$37,117
JanuviaSitagliptin Phosphate15$12,923
Repatha SyringeEvolocumab11$10,442
Repatha SureclickEvolocumab12$9,648
Rosuvastatin Calcium378$8,231
Diltiazem 24hr Er (Cd)Diltiazem Hcl179$7,881
Advair HfaFluticasone Propion/Salmeterol19$7,639
Metoprolol Succinate396$5,809

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$18$170,101117 claims
AstraZenecaFarxiga$127,016$51,79037 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Lancaster

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →